Company Reports Q1 Revenue of $99.6M, Below Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Reports Q1 revenue $99.6M, consensus $108.43M. "We continue to accelerate the development of our global pipeline, with numerous clinical trials underway across oncology and immunology," said CEO Samantha Du. "During the quarter, we made strong progress advancing zoci, with AACR data reinforcing its differentiated profile in both SCLC and epNECs, collaborations with Amgen and Boehringer Ingelheim to evaluate zoci as a potential backbone therapy, and rapid enrollment in the registrational DLLEVATE study...We also continue to advance our growing portfolio of global clinical programs, including ZL-1503 for atopic dermatitis...At the same time, our commercially profitable regional business provides a stable foundation, with several near-term opportunities expected to support future growth." "We are deepening our presence in key markets to capitalize on underlying demand for VYVGART and are expanding our regional footprint as we prepare for the launch of KarXT in China in Q2," said COO Josh Smiley. "KarXT's launch positions us to bring the first novel therapy in decades to this critical market, with potential NRDL inclusion next year. In addition, we anticipate a potential regulatory approval for TIVDAK this year, and with positive Phase 3 readouts for povetacicept and elegrobart, we have additional opportunities for future growth."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZLAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZLAB
Wall Street analysts forecast ZLAB stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.070
Low
25.70
Averages
47.93
High
74.00
Current: 17.070
Low
25.70
Averages
47.93
High
74.00
About ZLAB
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zai Lab's Tivdak Approved in China for Cervical Cancer Treatment
- Drug Approval: Zai Lab's Tivdak has received approval from China's National Medical Products Administration as a treatment for late-line cervical cancer patients, marking a significant advancement for the company in the biopharmaceutical sector.
- Clinical Trial Support: The approval is supported by data from the global Phase 3 trial innovaTV 301, which indicated that Tivdak significantly improved overall survival compared to chemotherapy in the targeted patient population, particularly among Chinese patients.
- Market Potential: With approximately 150,000 cervical cancer diagnoses annually in China, and limited treatment options for recurrent or metastatic cases, the launch of Tivdak offers new hope for these patients and addresses a critical market need.
- Strategic Partnership: In 2022, Zai Lab secured exclusive rights to develop and commercialize Tivdak in mainland China, Hong Kong, Macau, and Taiwan, further solidifying its strategic partnership with Pfizer and Genmab, thereby enhancing its competitive position in the biopharmaceutical market.
See More
TIVDAK Approved in China for Cervical Cancer Treatment
- First ADC Approval: TIVDAK is the first antibody-drug conjugate approved in China for the treatment of recurrent or metastatic cervical cancer, marking a significant breakthrough in this area and expected to provide new treatment options for patients.
- Clinical Trial Success: In the global Phase 3 innovaTV 301 clinical trial, TIVDAK demonstrated a statistically significant overall survival benefit, particularly in the China subpopulation, with a 45% reduction in the risk of death, providing strong clinical evidence for its approval in China.
- Broad Regulatory Approvals: TIVDAK has received approvals in multiple regions including the U.S., Japan, and the EU, showcasing the extensive global clinical evidence supporting its availability in China, thereby enhancing its competitive position in the market.
- Significant Market Potential: With approximately 150,000 new cervical cancer cases annually in China, the introduction of TIVDAK will bring hope to a patient population with limited treatment options, and is expected to significantly increase Zai Lab's market share in the Chinese gynecologic oncology sector.
See More
Analysts Favor Investment in China's AI Stocks
- Clear Investment Theme: Analysts agree that despite slowing economic growth in China, AI-related stocks represent the most obvious investment theme right now, with over half of the holdings in new funds focused on semiconductors and high-tech manufacturing, indicating confidence in future growth.
- Weak Consumer Performance: China's retail sales growth in April marked the lowest since the end of the pandemic, highlighting ongoing weakness in the consumer market, while tech stocks exhibit uneven performance, reflecting challenges in the overall economic environment.
- Market Dynamics Shift: In the past two months, a rotation in tech stocks has occurred, with increased investor focus on semiconductors, hard tech, and software, indicating a growing demand for these segments, particularly in the A-share market.
- Divergent Investment Strategies: Mironov holds large positions in Tencent and Alibaba, while Morgan Stanley favors AI model companies like Zhipu and MiniMax, showcasing a divergence in market views on investment strategies and perceptions of sustainable business models.
See More
Zai Lab Leadership Change to Enhance Efficiency
- Executive Departure: Zai Lab's President and COO Josh Smiley has left the company immediately as part of a leadership shake-up aimed at improving operational efficiency, indicating a critical reassessment of management structure at a pivotal time.
- Drug Launch Preparations: This executive change comes just before the anticipated launch of COBENFY™ in China, which may impact the company's strategic direction and competitive positioning in the market.
- Clinical Trial Developments: Zai Lab expects to announce key clinical trial results for its main cancer therapies later this year, which will significantly influence the company's future market performance and investor confidence.
- FDA Fast Track Status: The company's cancer drug Zocilurtatug Pelitecan has received FDA fast track designation, with Phase III enrollment completion targeted for the first half of 2027, highlighting Zai Lab's ongoing advancements in oncology treatment.
See More
Zai Lab Announces Senior Leadership Changes
- Leadership Change: Zai Lab announced that President and COO Josh Smiley will depart the company effective May 22, a move aimed at strengthening operational performance and efficiency, reflecting strategic adjustments in the executive team to address market challenges.
- Clinical Data Outlook: The company anticipates multiple clinical data readouts in 2026, including first-in-human data for zoci targeting ES-SCLC and extrapulmonary NECs, which could significantly advance its global pipeline and enhance investor confidence.
- Product Launch Preparation: Zai Lab is preparing for the launch of COBENFY™ in China while actively seeking multiple regional regulatory approvals, which will help the company secure a competitive edge in the rapidly evolving biopharmaceutical market.
- Company Vision: Zai Lab is focused on developing innovative products to address significant unmet medical needs in oncology, immunology, and neuroscience, with a strategic direction aimed at enhancing its impact on human health in the future.
See More
Zai Lab Receives FDA Fast Track Designation for Zoci
- FDA Fast Track Designation: Zai Lab's zoci (ZL-1310) has received Fast Track Designation from the FDA for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs), marking significant progress in addressing a major unmet medical need.
- Positive Clinical Trial Data: At the AACR Annual Meeting, zoci demonstrated an objective response rate (ORR) of 38.2% in heavily pretreated patients, indicating promising antitumor activity and potential new treatment options for patients.
- Advancing Registration Plans: Zai Lab is actively engaging with health authorities to advance the registration plan for zoci, aiming to expedite clinical development and meet the urgent needs of epNECs patients.
- Global Market Potential: The development of zoci may not only position Zai Lab for its first global oncology launch but also includes plans for three registration-enabling studies by the end of 2026, highlighting its broad prospects in the global market.
See More
Zai Lab's Tivdak Approved in China for Cervical Cancer Treatment
- Drug Approval: Zai Lab's Tivdak has received approval from China's National Medical Products Administration as a treatment for late-line cervical cancer patients, marking a significant advancement for the company in the biopharmaceutical sector.
- Clinical Trial Support: The approval is supported by data from the global Phase 3 trial innovaTV 301, which indicated that Tivdak significantly improved overall survival compared to chemotherapy in the targeted patient population, particularly among Chinese patients.
- Market Potential: With approximately 150,000 cervical cancer diagnoses annually in China, and limited treatment options for recurrent or metastatic cases, the launch of Tivdak offers new hope for these patients and addresses a critical market need.
- Strategic Partnership: In 2022, Zai Lab secured exclusive rights to develop and commercialize Tivdak in mainland China, Hong Kong, Macau, and Taiwan, further solidifying its strategic partnership with Pfizer and Genmab, thereby enhancing its competitive position in the biopharmaceutical market.
See More
TIVDAK Approved in China for Cervical Cancer Treatment
- First ADC Approval: TIVDAK is the first antibody-drug conjugate approved in China for the treatment of recurrent or metastatic cervical cancer, marking a significant breakthrough in this area and expected to provide new treatment options for patients.
- Clinical Trial Success: In the global Phase 3 innovaTV 301 clinical trial, TIVDAK demonstrated a statistically significant overall survival benefit, particularly in the China subpopulation, with a 45% reduction in the risk of death, providing strong clinical evidence for its approval in China.
- Broad Regulatory Approvals: TIVDAK has received approvals in multiple regions including the U.S., Japan, and the EU, showcasing the extensive global clinical evidence supporting its availability in China, thereby enhancing its competitive position in the market.
- Significant Market Potential: With approximately 150,000 new cervical cancer cases annually in China, the introduction of TIVDAK will bring hope to a patient population with limited treatment options, and is expected to significantly increase Zai Lab's market share in the Chinese gynecologic oncology sector.
See More
Analysts Favor Investment in China's AI Stocks
- Clear Investment Theme: Analysts agree that despite slowing economic growth in China, AI-related stocks represent the most obvious investment theme right now, with over half of the holdings in new funds focused on semiconductors and high-tech manufacturing, indicating confidence in future growth.
- Weak Consumer Performance: China's retail sales growth in April marked the lowest since the end of the pandemic, highlighting ongoing weakness in the consumer market, while tech stocks exhibit uneven performance, reflecting challenges in the overall economic environment.
- Market Dynamics Shift: In the past two months, a rotation in tech stocks has occurred, with increased investor focus on semiconductors, hard tech, and software, indicating a growing demand for these segments, particularly in the A-share market.
- Divergent Investment Strategies: Mironov holds large positions in Tencent and Alibaba, while Morgan Stanley favors AI model companies like Zhipu and MiniMax, showcasing a divergence in market views on investment strategies and perceptions of sustainable business models.
See More
Zai Lab Leadership Change to Enhance Efficiency
- Executive Departure: Zai Lab's President and COO Josh Smiley has left the company immediately as part of a leadership shake-up aimed at improving operational efficiency, indicating a critical reassessment of management structure at a pivotal time.
- Drug Launch Preparations: This executive change comes just before the anticipated launch of COBENFY™ in China, which may impact the company's strategic direction and competitive positioning in the market.
- Clinical Trial Developments: Zai Lab expects to announce key clinical trial results for its main cancer therapies later this year, which will significantly influence the company's future market performance and investor confidence.
- FDA Fast Track Status: The company's cancer drug Zocilurtatug Pelitecan has received FDA fast track designation, with Phase III enrollment completion targeted for the first half of 2027, highlighting Zai Lab's ongoing advancements in oncology treatment.
See More
Zai Lab Announces Senior Leadership Changes
- Leadership Change: Zai Lab announced that President and COO Josh Smiley will depart the company effective May 22, a move aimed at strengthening operational performance and efficiency, reflecting strategic adjustments in the executive team to address market challenges.
- Clinical Data Outlook: The company anticipates multiple clinical data readouts in 2026, including first-in-human data for zoci targeting ES-SCLC and extrapulmonary NECs, which could significantly advance its global pipeline and enhance investor confidence.
- Product Launch Preparation: Zai Lab is preparing for the launch of COBENFY™ in China while actively seeking multiple regional regulatory approvals, which will help the company secure a competitive edge in the rapidly evolving biopharmaceutical market.
- Company Vision: Zai Lab is focused on developing innovative products to address significant unmet medical needs in oncology, immunology, and neuroscience, with a strategic direction aimed at enhancing its impact on human health in the future.
See More
Zai Lab Receives FDA Fast Track Designation for Zoci
- FDA Fast Track Designation: Zai Lab's zoci (ZL-1310) has received Fast Track Designation from the FDA for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs), marking significant progress in addressing a major unmet medical need.
- Positive Clinical Trial Data: At the AACR Annual Meeting, zoci demonstrated an objective response rate (ORR) of 38.2% in heavily pretreated patients, indicating promising antitumor activity and potential new treatment options for patients.
- Advancing Registration Plans: Zai Lab is actively engaging with health authorities to advance the registration plan for zoci, aiming to expedite clinical development and meet the urgent needs of epNECs patients.
- Global Market Potential: The development of zoci may not only position Zai Lab for its first global oncology launch but also includes plans for three registration-enabling studies by the end of 2026, highlighting its broad prospects in the global market.
See More
